Facebook Twitter YouTube Google Plus

An Interview with Aduro Biotech

If the audio player does not appear above, click here.

Drs. Natalie Sacks & Evan Alley

In this session, our guests on behalf of Aduro Biotech were Natalie Sacks, MD, the chief medical officer at Aduro, and Evan Alley, MD, PhD, the chief of the Division of Hematology and Oncology at Penn Medicine. Drs. Sacks and Alley discussed Aduro Biotech's upcoming clinical trial, which seeks to evaluate the effectiveness of their CRS-207 vaccine in combination with pembrolizumab (Keytruda) in previously treated patients with pleural mesothelioma. CRS-207 is a weakened form of the Listeria bacteria modified to reduce its ability to cause infections, but still able to stimulate the immune system. Pemborlizumab (Keytruda) is a checkpoint inhibitor. Both drugs have singularly demonstrated activity in mesothelioma and preclinical data suggests a synergy in using a combined approach

Listen to more Meet the Mesothelioma Experts podcasts